TABLE 4.
Genotypic characterization of enterobacterial isolates and their transformants, β-lactamase isoelectric points and plasmid DNA sizes of transformants, and phenotypic characterization of non-β-lactam antibiotic resistance markers
| Isolate | PCRa
|
PCR (kb)a
|
Isoelectric point(s) | Plasmid size (kb) | Associated non-β-lactam antibiotic resistance markersb | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| blaTEM | blaSHV | blaOXA-10 | arr-2 | 5′ CS-blaVEB-1 | blaVEB-1-3′ CS | blaVEB-1-arr-2 | blaVEB-1-blaOXA-10 | ||||
| E. coli 1 | + | − | + | + | Sp Ka Tb Ss Sx Cl Na Pe Ra | ||||||
| Transformant | + | − | + | + | 0.1 | 6.3; 0.8 | 0.7 | 3 | 7.4; 6.3; 5.4 | 210 | Sp Ka Ss Cl Ra |
| E. coli 2 | + | − | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 4.5 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 3 | − | + | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 8.2; 2.3 | 1.8 | 5 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 4 | + | − | + | + | Sp Ka Tb Ss Sx Cl Na Pe Ra | ||||||
| Transformant | − | − | + | + | 4.2 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 5 | + | − | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 210 | Sp Ka Tb Ss Sx Cl Te Ra |
| E. coli 6 | + | − | + | + | Sp Ka Tb Ss Sx Cl Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 7 | + | − | + | + | Sp Ka Tb Ss SX Cl Te Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 8 | + | − | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 8.6 | − | 5 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Te |
| E. coli 9 | − | − | + | + | Sp Ka Tb Ss Cl Te Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Cl Ra |
| E. coli 10 | + | − | + | + | Sp Ka Tb Ss Sx Cl Te Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 210 | Sp Cl Ra |
| E. cloacae 11 | − | − | − | + | Ka Tb Ra | ||||||
| Transformant | − | − | − | + | 1.3 | 3.9 | − | − | 7.4 | 150 | Ka |
| E. cloacae 12 | − | − | − | + | Ka Tb Ra | ||||||
| Transformant | − | − | − | + | 1.3 | 3.9 | − | − | 7.4 | 150 | Ka |
| E. cloacae 13 | + | + | + | + | Sp Ka Tb Ss Sx Cl Te Ra | ||||||
| Transformant | + | − | − | + | 0.1 | 0.8 | − | 3 | 7.4; 6.3; 5.4 | 100 | Ka Tb Ss Sx Ra |
| E. cloacae 14 | + | − | − | + | Sp Ka Tb Ss Sx Cl Ra | ||||||
| Transformant | − | − | − | + | 0.1 | 0.8 | − | − | 7.4; 6.5 | 24 | Ss |
| E. sakazakii 15 | + | − | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | + | − | + | + | 1.7 | 4.8 | 0.7 | 3 | 7.4; 6.3; 5.4 | 150 | Ka Tb Te Ra |
| K. pneumoniae 16 | − | + | + | + | Sp Ka Tb Ss Sx Ra | ||||||
| Transformant | − | − | + | + | 2.3 | 6.5 | 0.7 | 3 | 7.4; 6.3 | 150 | Sp Ka Tb Ss Ra |
| K. pneumoniae 17 | − | + | + | + | Sp Ka Tb Ss Sx Cl Te Na Pe Ra | ||||||
| Transformant | − | − | + | + | 1.4 | 4.8 | 0.7 | 3 | 7.4; 6.3 | 210 | Sp Ka Tb Ss Sx Cl Te Ra |
| K. pneumoniae 18 | + | + | + | + | Sp Ka Tb Ss Sx Cl Te Ra | ||||||
| Transformant | + | − | + | + | 0.1 | 6.3; 0.8 | 0.7 | 3 | 7.4; 6.3; 5.4 | 210 | Sp Ka Ss Cl Ra |
a
Minus (−) indicates that no PCR product was obtained.
b
Antibiotic resistance markers: Sp, spectinomycin; Ka, kanamycin; Tb, tobramycin; Ss, sulfonamides; Sx, trimethroprim-sulfamethoxazole; Cl, chloramphenicol; Te, tetracycline; Na, nalidixic acid; Pe, pefloxacin; Ra, rifampin.